Phase I Trial of a PSA based vaccine and ipilimumab in patients (pts) with metastatic castrate resistant prostate cancer (CRPC)

被引：0
|
作者：
Gulley, James L. [1 ]
Arlen, Philip M. [1 ]
Madan, Ravi [1 ]
Lechleider, Robert L. [1 ]
Dahut, William L. [1 ]
Lowy, Israel [2 ]
Schlom, Jeffrey [1 ]
机构：
[1] NCI, Bethesda, MD USA
[2] Medarex, Princeton, NJ USA
来源：
MOLECULAR CANCER THERAPEUTICS | 2007年 / 6卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：3381S / 3381S
页数：1
相关论文
共 50 条
  • [1] Phase I trial of a targeted therapy with a psa-based vaccine and ipilimumab in patients (pts) with metastatic castrate-resistant prostate cancer (CRPC)
    Gulley, J.
    ANNALS OF ONCOLOGY, 2008, 19 : 24 - 24
  • [2] A phase I study of testosterone in patients (pts) with early castrate resistant prostate cancer (CRPC)
    Knight, D. A.
    Mohile, S. G.
    Posadas, E. M.
    Manchen, E. A.
    Stadler, W. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [3] Phase I trial of targeted therapy with PSA-TRICOM vaccine (V) and ipilimumab (ipi) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
    Gulley, James L.
    Madan, Ravi A.
    Tsang, Kwong Y.
    Jochems, Caroline
    Dahut, William L.
    Schlom, Jeffrey
    CANCER RESEARCH, 2013, 73
  • [4] Phase I trial of targeted therapy with PSA-TRICOM vaccine (V) and ipilimumab (ipi) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
    Mohebtash, M.
    Madan, R. A.
    Arlen, P. M.
    Rauckhorst, M.
    Tsang, K. Y.
    Cereda, V.
    Vergati, M.
    Poole, D. J.
    Dahut, W. L.
    Schlom, J.
    Gulley, J. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [5] A phase II trial of cabozantinib (Cabo) in patients (pts) with castrate-resistant prostate cancer (CRPC) metastatic to bone (NCT01428219).
    Grivas, Petros
    Daignault, Stephanie
    Cooney, Kathleen A.
    Jacobson, Jon
    Yablon, Corrie
    Ross, Brian Dale
    Chenevert, Thomas L.
    Galban, Craig J.
    Rehemtulla, Alnawaz
    Keller, Evan T.
    Kunju, Priya
    Mehra, Rohit
    Escara-Wilke, June
    Shelley, Greg
    Pienta, Kenneth James
    Hussain, Maha
    Smith, David C.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [6] A xenogeneic PSMA DNA vaccine for patients (pts) with non-castrate metastatic (NCMPC) and castrate metastatic prostate cancer (CMPC)-A phase I trial of proof of principle
    Slovin, S.
    Gregor, P.
    Wolchok, J.
    Pedraza, A.
    Orlandi, F.
    Jefferson, M.
    Jefferson, M.
    Fernandez, C.
    Rudolph, J.
    Houghton, A.
    Scher, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [7] Cytokine changes in castrate metastatic prostate cancer (CPMC) patients (pts) treated with ipilimumab (Ipi)
    Yuan, J.
    Orlandi, F.
    Jefferson, M.
    Li, H.
    Gallardo, H.
    Ku, G.
    Wolchok, J.
    Scher, H.
    Allison, J.
    Slovin, S. F.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [8] A Phase I vaccine study with metastatic tumour as the antigen source in patients with advanced castrate-resistant prostate cancer
    Gardiner, R. A.
    Schmidt, C.
    Ellem, K. A. O.
    Lopez, A.
    Scells, B.
    O'Connor, L.
    Nicol, D. L.
    McClintock, P.
    Yaxley, J.
    BJU INTERNATIONAL, 2009, 103 : 12 - 13
  • [9] Phase II trial of bevacizumab monotherapy in nonmetastatic castrate-resistant prostate cancer (CRPC)
    Ogita, S.
    Tejwani, S.
    Heilbrun, L. K.
    Fontana, J. A.
    Heath, E. I.
    Freeman, S.
    Smith, D. W.
    Baranowski, K.
    Vaishampayan, U. N.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [10] A Disease Progression Model of Castrate Resistant Prostate Cancer (CRPC) Using Prostate Specific Antigen (PSA)
    Gray, Elizabeth
    Mai, Tu H.
    Sharma, Manish R.
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2015, 42 : S76 - S77
12345